Page last updated: 2024-11-07

u 69593

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

U 69593: selective ligand for opioid K-receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID105104
CHEMBL ID440765
CHEBI ID73357
SCHEMBL ID726034
MeSH IDM0132113

Synonyms (54)

Synonym
gtpl1656
gtpl1655
[3h]-u69593
n-methyl-2-phenyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
u-69593, solid
benzeneacetamide, n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-, (5alpha,7alpha,8beta)-(-)-
u 69,593
u 69593
(+)-(5alpha,7alpha,8beta)-n-methyl-n-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide
benzeneacetamide, n-methyl-n-[(5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
u69593
96744-75-1
1-oxaspiro[4.5]decane, benzeneacetamide deriv.
benzeneacetamide, n-methyl-n-[(5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]- (9ci)
benzeneacetamide, n-methyl-n-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-, [5r-(5alpha,7alpha,8beta)]-
n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl]acetamide
[3h]u69593
bdbm21130
u69,593
n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzeneacetamide
u-69593
NCGC00163179-01
benzeneacetamide, n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-
PDSP2_001518 ,
u-69,593
CHEMBL440765
chebi:73357 ,
n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]dec-8-yl]acetamide
NCGC00163179-02
cas-96744-75-1
tox21_112026
dtxsid3046326 ,
n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-benzeneacetamide
dtxcid1026326
j5s4k6tktg ,
unii-j5s4k6tktg
BCP0726000202
(5alpha,7alpha,8beta)-(-)-n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-benzeneacetamide
SCHEMBL726034
tox21_112026_1
NCGC00163179-03
n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)benzeneacetamide
PGZRDDYTKFZSFR-ONTIZHBOSA-N
n-methyl-2-phenyl-n-((5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide
(+)-n-methyl-2-phenyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
AS-16910
Q7862883
n-methyl-2-phenyl-n-(7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide
AKOS037643567
u069593
WDA74475
CS-0011105
u 69593;u69593;benzeneacetamide, n-methyl-n-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-, [5r-(5,7,8)]-; 1-oxaspiro[4.5]decane, benzeneacetamide deriv.
HY-12363

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The fentanyl concentrations derived by both methods were compared by linear regression and pharmacokinetic analysis."( Comparison of liquid chromatography-mass spectrometry and radioimmunoassay for measurement of fentanyl and determination of pharmacokinetics in equine plasma.
Mama, KR; Stanley, SD; Thomasy, SM,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects of the kappa opioid agonists, spiradoline (U62,066), enadoline (CI-977) and U69,593, were examined alone and in combination with the opioid antagonists quadazocine and beta-funaltrexamine in squirrel monkeys that responded under a schedule of shock titration."( Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Dykstra, LA; Pitts, RC, 1994
)
0.29

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" To develop stable and orally bioavailable analogues of DN-9, eight lactam-bridged cyclic analogues of DN-9 between positions 2 and 5 were designed, synthesized, and biologically evaluated."( Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
Chen, D; Fang, Q; Li, N; Niu, J; Shi, X; Shi, Y; Xiao, J; Xu, B; Xu, K; Zhang, M; Zhang, Q; Zhang, R, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" At all pretreatment times, the antinociceptive dose-response lines for these kappa agonists were displaced to the right to various degrees in a parallel fashion; an increasing rightward displacement of the U69,593 and bremazocine antinociceptive dose-response lines was observed at 1 and 3 days after a single nor-BNI pretreatment, with a gradual return toward the control level at later times after pretreatment."( Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.
Horan, P; Porreca, F; Taylor, J; Yamamura, HI, 1992
)
0.28
" Graded dose-response curves (DRC) were constructed from tail-flick latencies converted to % maximal possible effect (%MPE), and the ED50 calculated."( Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: isobolographic analysis.
Green, J; Harris, S; Lloyd, P; Lozito, R; Messineo, E; Ossipov, MH, 1990
)
0.28
" The kappa-selective antagonist, norbinaltorphimine, also failed to shift the dose-response curve to U50488H in this test, despite producing considerable antagonism of the U50488H effect in the rotarod test and of U69593 in both experimental situations."( Evidence that the kappa agonist U50488H has non-opioid actions.
Birch, PP; Cavicchini, E; Hayes, AG, 1988
)
0.27
"6-fold rightward shift of the U69,593 dose-response line."( Lack of cross-tolerance between U69,593 and bremazocine suggests kappa-opioid receptor multiplicity in mice.
Horan, PJ; Porreca, F, 1993
)
0.29
" The 2 d agonist exposure (1 microM) caused a shift in the U69,593 dose-response curve that was greater in the potassium-stimulated paradigm (140-fold) than in the spontaneous release assay (sixfold)."( kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.
Dalman, FC; O'Malley, KL, 1999
)
0.3
" Insulin pretreatment shifted the dose-response curve for activation of KOR by increasing the maximal response without changing the EC(50) value for."( Tyrosine phosphorylation of the kappa -opioid receptor regulates agonist efficacy.
Appleyard, SM; Chavkin, C; McLaughlin, JP, 2000
)
0.31
" The Ca(2+) response occurred in all-or-none fashion and the half-maximal dosage of U50488H (812."( Cyclic AMP regulates the calcium transients released from IP(3)-sensitive stores by activation of rat kappa-opioid receptors expressed in CHO cells.
Allen, CN; Grandy, DK; Ikeda, M; Nelson, CS; Shinagawa, H; Shinoe, T; Sugiyama, T; Yoshioka, T, 2001
)
0.31
" Following chronic treatment, dose-response profiles to QNP were obtained to assess the expression of sensitization; the effect of U69593 on locomotor activity in animals already sensitized to QNP was also assessed."( Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms.
Bisnaire, L; Graham, D; Hayton, S; Perreault, ML; Simms, J; Szechtman, H, 2006
)
0.33
" For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive."( In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Kuo, A; Meutermans, W; Smith, MT; Wyse, BD, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
kappa-opioid receptor agonistA compound that exhibits agonist activity at the kappa-opioid receptor.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
N-alkylpyrrolidine
organic heterobicyclic compound
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency13.37140.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency33.49150.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743069
cytochrome P450 2D6Homo sapiens (human)Potency7.76190.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)Ki0.00350.00350.15120.2990AID647796
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki1.14500.00322.28879.3160AID709667
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00200.00010.601710.0000AID55440
Delta-type opioid receptorMus musculus (house mouse)Ki1.00000.00000.53939.4000AID1165887; AID1188907
Kappa-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00060.00050.36987.0000AID95365
Kappa-type opioid receptorRattus norvegicus (Norway rat)Ki0.00260.00000.18683.9500AID1456283; AID148576; AID55440; AID65519; AID65522
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.19400.00010.813310.0000AID148357; AID150239; AID150825
Mu-type opioid receptorHomo sapiens (human)Ki2.75370.00000.419710.0000AID1197351; AID150841; AID150851; AID621887; AID647794; AID709667; AID749692; AID765827
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)3.64370.00020.75218.0140AID148081; AID148092; AID149748; AID150239
Delta-type opioid receptorHomo sapiens (human)Ki6.71400.00000.59789.9300AID1197353; AID147910; AID147914; AID148220; AID148228; AID149782; AID621888; AID647795; AID709666; AID749691; AID765826
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00210.00030.71237.0700AID148688
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00460.00000.20186.4240AID149131; AID149135; AID149844
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)0.05800.00001.201110.0000AID147862; AID147868; AID150239; AID480391
Kappa-type opioid receptorHomo sapiens (human)Ki0.24200.00000.362410.0000AID1138772; AID1197354; AID1434275; AID147987; AID147998; AID1802456; AID219259; AID488649; AID621889; AID647796; AID709669; AID749690; AID765825
Nociceptin receptorHomo sapiens (human)Ki10.00000.00000.03370.5000AID621019
Mu-type opioid receptorMus musculus (house mouse)Ki0.28850.00000.12281.3000AID1165886; AID1188906; AID149067; AID149131; AID149135
Nociceptin receptorCavia porcellus (domestic guinea pig)Ki0.69200.00110.17650.6920AID268677
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.58800.00020.660310.0000AID147868; AID149863
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.24640.00000.27869.0000AID147910; AID147914; AID149131; AID149135; AID268677
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)EC50 (µMol)0.33000.33001.26502.2000AID302202
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)EC50 (µMol)0.33000.33001.26502.2000AID302202
Kappa-type opioid receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00770.00040.00390.0180AID1164349
Kappa-type opioid receptorRattus norvegicus (Norway rat)Kd0.00100.00001.806910.0000AID1232261
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)10.00000.00000.32639.4000AID148345
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)10.00000.00000.43328.3000AID148070
Delta-type opioid receptorHomo sapiens (human)Kd1.98000.00040.51471.9800AID56281; AID56295
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)EC50 (µMol)1.44540.00000.20671.4454AID1875774
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Kd4.89400.00211.44444.8940AID95210; AID95211
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)0.18920.00000.22448.9900AID1129823; AID1138776; AID1165893; AID1167689; AID1171840; AID1185667; AID1188911; AID1224144; AID1245658; AID1393919; AID1393921; AID1441556; AID149996; AID1573399; AID1573401; AID1573402; AID1802457; AID1812976; AID1820697; AID1888745; AID268069; AID291861; AID302202; AID302207; AID365601; AID378997; AID378998; AID481112; AID659121; AID709664; AID724712
Mu-type opioid receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.00770.00000.04930.9320AID1164349
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Kd1.26720.00000.72092.1420AID138706; AID141494; AID141495; AID141497
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorHomo sapiens (human)ED501.98000.02601.33371.9800AID149616
Delta-type opioid receptorHomo sapiens (human)Emax0.17800.12400.15100.1780AID149617; AID56285
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Emax0.05800.05800.12740.1430AID95205
Kappa-type opioid receptorHomo sapiens (human)ED500.02400.00071.45698.9400AID147846
Mu-type opioid receptorCavia porcellus (domestic guinea pig)ED501.77750.31701.11532.1420AID152215; AID152216
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Emax0.17030.12300.14830.1770AID138842; AID138846; AID152217; AID152218
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
calcium-mediated signalingNociceptin receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayNociceptin receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayNociceptin receptorHomo sapiens (human)
sensory perceptionNociceptin receptorHomo sapiens (human)
sensory perception of painNociceptin receptorHomo sapiens (human)
response to estradiolNociceptin receptorHomo sapiens (human)
positive regulation of urine volumeNociceptin receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayNociceptin receptorHomo sapiens (human)
eating behaviorNociceptin receptorHomo sapiens (human)
negative regulation of cAMP-mediated signalingNociceptin receptorHomo sapiens (human)
estrous cycleNociceptin receptorHomo sapiens (human)
negative regulation of blood pressureNociceptin receptorHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNociceptin receptorHomo sapiens (human)
regulation of locomotor rhythmNociceptin receptorHomo sapiens (human)
conditioned place preferenceNociceptin receptorHomo sapiens (human)
neuropeptide signaling pathwayNociceptin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
nociceptin receptor activityNociceptin receptorHomo sapiens (human)
G protein-coupled receptor activityNociceptin receptorHomo sapiens (human)
protein bindingNociceptin receptorHomo sapiens (human)
neuropeptide bindingNociceptin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneNociceptin receptorHomo sapiens (human)
cytoplasmic vesicleNociceptin receptorHomo sapiens (human)
plasma membraneNociceptin receptorHomo sapiens (human)
neuron projectionNociceptin receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (236)

Assay IDTitleYearJournalArticle
AID1802456Homologous Competition Assay from Article 10.1074/jbc.M113.515668: \\Chemotype-selective modes of action of u00BF-opioid receptor agonists.\\2013The Journal of biological chemistry, Nov-29, Volume: 288, Issue:48
Chemotype-selective modes of action of κ-opioid receptor agonists.
AID1802457cAMP Inhibition Assay from Article 10.1074/jbc.M113.515668: \\Chemotype-selective modes of action of u00BF-opioid receptor agonists.\\2013The Journal of biological chemistry, Nov-29, Volume: 288, Issue:48
Chemotype-selective modes of action of κ-opioid receptor agonists.
AID1165886Displacement of [3H]DAMGO from mouse whole brain MOR2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.
AID148220Displacement of [3H]C1-DPDPE from human recombinant Opioid receptor delta 1 on CHO cell membranes.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID149135Binding affinity determined against Opioid receptor kappa 1 from a native receptor in guinea pig2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID1393919Agonist activity at human KOR expressed in CHO cells assessed as induction of beta-arrestin-2 recruitment by enzyme fragment complementation assay2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
AID149863Inhibitory concentration was determined against Opioid receptor mu 1 using [3H]- DAMGO radioligand1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.
AID709664Agonist activity at human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by [35S]GTPgammaS binding assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID488649Binding affinity to kappa opioid receptor2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.
AID709667Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID709663Selectivity index, ratio of KI for human delta opioid receptor to KI for human kappa opioid receptor2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID1581747Antinociceptive activity in Sprague-Dawley rat dosed intravenously using cumulative dosing every 5 mins until rat maxed-out on hot plate co-treated with 0.1 mg/kg naltrexone by hot plate test2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID1185653Displacement of [3H]U-69593 from kappa opioid receptor in guinea pig brain membranes after 2 hrs by scintillation counting analysis2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists.
AID1188906Displacement of [3H]DAMGO from mu opioid receptor in mouse whole brain without cerebellum2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.
AID148357Binding affinity towards Opioid receptor mu 1 by the displacement of [125I]Enkephalin; Not determined2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
3-Aryl pyridone derivatives. Potent and selective kappa opioid receptor agonists.
AID147868Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.
AID268677Displacement of radiolabeled DAMGO from mu opioid receptor in Hartley guinea pig brain2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
AID149572Ability to stimulate binding to kappa-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6 nM nor-binaltorphimine (nor-BNI); NS=no stimulation2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID147914Binding affinity of compound was determined against Opioid receptor mu 1 from native receptor in guinea pig2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID141497Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID1441556Agonist activity at recombinant human kappa-type opioid receptor expressed in HEK293 cells after 30 mins by [35S]GTPgammaS binding assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.
AID152218Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6000 nM CTAP2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID56284[35S]GTP-gamma-S, induced maximal stimulation ( E max ) Delta opioid receptor in guinea pig caudate membranes blocked with 20 nM NTI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1434275Displacement of [3H]U69593 from human KOR expressed in CHO cells2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
AID150851Binding affinity determined against Opioid receptor mu 1 from human cloned receptor2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID724714Selectivity ratio of Ki for mu opioid receptor in mouse whole brain membranes without cerebellum to Ki for kappa opioid receptor in guinea pig cerebellum2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID1188912Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding relative to U695932014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.
AID149617Ability to stimulate binding to delta-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 20 nM naltrindole (NTI)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID149019Tested for inhibitory effect on binding of [3H]DAMGO to opioid receptor mu in guinea pig cerebellum membranes1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
N-terminal alkylated derivatives of [D-Pro10]dynorphin A-(1-11) are highly selective for kappa-opioid receptors.
AID1812975Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation by measuring maximal efficacy preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and 2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID291862Activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay relative to U695932007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID1875772Displacement of [3H]-HS665 from KOR in guinea pig brain membranes2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved
AID647795Displacement of [3H]-DADLE from human delta opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting2012European journal of medicinal chemistry, Apr, Volume: 50Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
AID1138776Agonist activity at human kappa opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
AID1197354Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method2015European journal of medicinal chemistry, Mar-06, Volume: 92Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID378999Agonist activity at human kappa opioid receptor-Galpha-16 fusion protein expressed in CHO cells by calcium flux assay relative to U695932006Journal of natural products, Jan, Volume: 69, Issue:1
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
AID148826Binding affinity at Opioid receptor kappa 1 in guinea pig brain membrane determined by using [3H]U-69593 as radioligand1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Effects of addition of a 2-methyl group to ethyl nipecotates (beta-meperidines) on receptor affinities and opiate agonist/antagonist activities.
AID148092Inhibition of [125I]deltorphin binding to human delta opioid receptor from membranes of HEK293 cells2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.
AID147846Effective dose for agonistic activity towards human kappa opioid receptor from membranes of HEK293 cells was determined by radiolabeled [35S]GTP-gamma-S, assay2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.
AID268068Stimulation of [35S]GTPgammaS binding in human brain cortical membrane relative to control2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
AID149749Tested for inhibitory concentration against [3H]DPDPE binding at sites of delta-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID1573402Agonist activity at human kappa opioid receptor expressed in human U2OS cells assessed as increase in ERK1/2 phosphorylation after 10 mins by Western blot analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID219259Binding affinity towards Wild-type kappa opioid receptor expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID1441545Displacement of [3H]U-69,593 from kappa-type opioid receptor in guinea pig brain membranes after 120 mins by solid scintillation counting2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.
AID147862Binding affinity towards Opioid receptor kappa 1 by the displacement of [125I]-(D-Pro10)-Dynorphin A2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
3-Aryl pyridone derivatives. Potent and selective kappa opioid receptor agonists.
AID149659Binding affinity at opioid receptor delta 1 by displacement of [3H]DADLE in rat brain membrane2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID56295Binding affinity against Delta opioid receptor in using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 20 nM NTI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID150239Inhibitory concentration was determined against Opioid receptors using [3H]- bremazocine radioligand1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.
AID481112Agonist activity at human recombinant kappa opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding after 45 mins by microplate luminescence assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
AID749692Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID149124Binding affinity at Opioid receptor kappa 1 by displacement of [3H]U-69593 in guinea pig brain membranes2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID1197351Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method2015European journal of medicinal chemistry, Mar-06, Volume: 92Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID1188911Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.
AID95365Binding affinity against rat kappa-opioid receptor expressed in CHO cells was determined by competitive inhibition of 2 nM [3H]-U 695931998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Syntheses of potent Leu-enkephalin analogs possessing beta-hydroxy-alpha,alpha-disubstituted-alpha-amino acid and their characterization to opioid receptors.
AID95210Binding affinity against kappa opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID232232Selectivity given as ratio of kappa receptor to delta receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID709666Displacement of [3H]pCl-DPDPE from human delta opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1875774Agonist activity at KOR in guinea pig brain membranes assessed as stimulation of [35S]GTPgammaS binding measured after 1 hr by liquid scintillation counting analysis2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved
AID378997Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding2006Journal of natural products, Jan, Volume: 69, Issue:1
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
AID1573401Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID141256Binding affinity towards Mutant D216N, D217N, E218Q Opioid receptor kappa 1 EL-2 expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID138841[35S]GTP-gamma-S, induced maximal stimulation ( E max ) against Mu opioid receptor in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1188907Displacement of [3H]DPDPE from delta opioid receptor in mouse whole brain without cerebellum2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.
AID621889Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
AID1171840Agonist activity at human KOR expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by luminescence assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.
AID141489Tested for inhibitory concentration against [3H]DAMGO binding at sites of mu-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID147998Binding affinity against opioid receptor kappa 1 from human cloned receptor2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID268071Ratio for stimulation of [35S]GTP-gamma-S binding to kappa opioid receptor in human brain cortical membrane in absence to presence of norBNI2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
AID95204[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Kappa opioid receptor in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1812976Agonist activity at KOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competiti2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID95205[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Kappa opioid receptor in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID1165887Displacement of [3H]DPDPE from mouse whole brain DOR2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.
AID147987Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID724713Selectivity ratio of Ki for delta opioid receptor in mouse whole brain membranes without cerebellum to Ki for kappa opioid receptor in guinea pig cerebellum2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID1812978Agonist activity at DOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competiti2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID709669Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID1812979Agonist activity at DOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competiti2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID95211Binding affinity against kappa opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID152215Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes under unblocked condition2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID148081Binding affinity towards Opioid receptor delta 1 by the displacement of [125I]-Deltorphin2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
3-Aryl pyridone derivatives. Potent and selective kappa opioid receptor agonists.
AID302208Efficacy at human kappa opioid receptor assessed as inhibition of Galpha-16-induced calcium flux relative to U69,5932007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
AID481095Displacement of [3H]U69593 from kappa opioid receptor in guinea pig brain membrane after 150 mins by scintillation counting2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
AID1129824Agonist activity at kappa opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation at 1 uM after 30 mins2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.
AID1573399Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID709665Selectivity index, ratio of KI for human mu opioid receptor to KI for human kappa opioid receptor2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID228523Tested for ratio between opioid receptor kappa and opioid receptor mu binding; 1/5201992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
N-terminal alkylated derivatives of [D-Pro10]dynorphin A-(1-11) are highly selective for kappa-opioid receptors.
AID232233Selectivity given as ratio of mu receptor to delta receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID152216Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6000 nM CTAP2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID141495Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID1165888Displacement of [3H]U-69593 from guinea pig cerebellum KOR2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.
AID1164343Displacement of [3H]U69593 from kappa opioid receptor in Wistar rat brain membranes by liquid scintillation counting based competition binding assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Novel cyclic biphalin analogue with improved antinociceptive properties.
AID149131Binding affinity for the Opioid receptor kappa 11988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1393921Agonist activity at human KOR expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by HTRF assay2018Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
AID149996Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID150841Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID1167689Agonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Design, synthesis, and structure-activity relationship of novel opioid κ receptor selective agonists: α-iminoamide derivatives with an azabicyclo[2.2.2]octene skeleton.
AID302207Agonist activity at human kappa opioid receptor assessed as inhibition of Galpha-16-induced calcium flux2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
AID1812977Agonist activity at KOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation by measuring maximal efficacy preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and 2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID233860Selectivity between kappa opioid receptor and delta opioid receptor.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID151009Percent stimulation of [35S]GTP-gamma-S, binding in recombinant human Opioid receptor mu 1 transfected into CHO cells2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID1581749Toxicity in Sprague-Dawley rat assessed as induction of hypothermia at 0.0032 to 10 mg/kg, iv2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID621020Selectivity ratio of Ki for human MOP receptor to Ki for human NOP receptor2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
AID65519Binding constant against E203Q,D204N,D206N EL-2 Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID709668Agonist activity at human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by [35S]GTPgammaS binding assay relative to U69,5932012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
AID378998Agonist activity at human kappa opioid receptor-Galpha-16 fusion protein expressed in CHO cells by calcium flux assay2006Journal of natural products, Jan, Volume: 69, Issue:1
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
AID724712Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by [35S]-GTPgammaS binding assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID765826Displacement of [3H]DADLE from human delta opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting2013European journal of medicinal chemistry, Sep, Volume: 67Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.
AID1138772Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
AID621887Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
AID1245658Agonist activity at human KOR expressed in CHO cell membranes by [35S]GTPgammaS binding assay2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.
AID1188908Displacement of [3H]U69593 from kappa opioid receptor in guinea pig cerebellum2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.
AID291861Antagonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID1185667Agonist activity at human kappa opioid receptor expressed in HEK-293 cells assessed as stimulation of [35S]-GTPgammaS binding after 30 mins by liquid scintillation counting analysis2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists.
AID1812974Agonist activity at MOR (unknown origin) expressed in HEK293-A cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 30 mins in presence of 3-isobutyl-1-methylxanthine followed by forskolin and compound addition by competiti2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.
AID1875771Displacement of [3H]-HS665 from DOR in rat brain membranes2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved
AID148691Tested for inhibitory concentration against [3H]U-69593 binding at sites of kappa-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID148345Stimulation of [35S]GTP-gamma-S, binding to recombinant human Opioid receptor mu 1 expressed in CHO cells2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID150825Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.
AID647794Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting2012European journal of medicinal chemistry, Apr, Volume: 50Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
AID148162Percent stimulation of [35S]GTP-gamma-S, binding in recombinant human Opioid receptor kappa 1 transfected into CHO cells2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID148688Inhibitory concentration against Opioid receptor kappa 1 using [3H]- U-69,593 radioligand1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.
AID749690Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID724711Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by [35S]-GTPgammaS binding assay relative to control2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID268678Displacement of radiolabeled DPDPE-Cl from delta opioid receptor in Hartley guinea pig brain2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
AID148576Binding constant against wild type EL-2 Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID65522Binding constant against E203Q,D204N,D206N,E209Q EL-2 Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID1164348Agonist activity at rat kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to untreated control2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Novel cyclic biphalin analogue with improved antinociceptive properties.
AID148724Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for D138A point mutations; No binding1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID1456283Displacement of [3H]U-69,593 from kappa opioid receptor in rat brain after 60 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.
AID724717Displacement of [3H]DAMGO from mu opioid receptor in mouse whole brain membranes without cerebellum after 1 hr by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID148101Tested for inhibitory effect on binding of [3H]bremazocine to opioid receptor kappa in guinea pig cerebellum membranes1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
N-terminal alkylated derivatives of [D-Pro10]dynorphin A-(1-11) are highly selective for kappa-opioid receptors.
AID148382Percent stimulation of [35S]GTP-gamma-S, binding to recombinant human Opioid receptor delta 1 expressed in CHO cells2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID56281Binding affinity against Delta opioid receptor in using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 20 nM NTI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1138783Displacement of [3H]Cl-DPDPE from human delta opioid receptor transfected in CHO cell membranes after 60 mins2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
AID138842[35S]GTP-gamma-S, induced maximal stimulation ( E max ) against Mu opioid receptor in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID141261Binding affinity towards Mutant E203Q, D204N, D206N, Opioid receptor kappa 1 EL-2 expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID138845[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Mu opioid receptor in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID724715Displacement of [3H]U69593 from kappa opioid receptor in guinea pig cerebellum after 1 hr by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID56285[35S]GTP-gamma-S, induced maximal stimulation ( E max ) Delta opioid receptor in guinea pig caudate membranes blocked with 20 nM NTI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID480391Displacement of [3H]naloxone from kappa opioid receptor expressed in HEK293 cell membrane2010Journal of natural products, May-28, Volume: 73, Issue:5
Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica.
AID268679Displacement of radiolabeled U69593 from kappa1 opioid receptor in Hartley guinea pig brain2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
AID765825Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting2013European journal of medicinal chemistry, Sep, Volume: 67Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.
AID1164349Agonist activity at rat kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Novel cyclic biphalin analogue with improved antinociceptive properties.
AID1875770Displacement of [3H]-HS665 from MOR in rat brain membranes2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved
AID1888745Agonist activity at human kappa opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 2 hrs by scintillation counting method2022Bioorganic & medicinal chemistry, 01-01, Volume: 53Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.
AID148070Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID1581745Antinociceptive activity in Sprague-Dawley rat dosed intravenously using cumulative dosing every 5 mins until rat maxed-out on hot plate by hot plate test2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
AID149616Ability to stimulate binding to delta-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 20 nM naltrindole (NTI)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID1165893Agonist activity at human KOR expressed in CHO cells by [35S]GTPgammaS binding assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.
AID1224144Agonist activity at recombinant kappa-opioid receptor in human HEK293 cells by [35S]-GTP-gammaS binding assay2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Combination of cyclohexane and piperazine based κ-opioid receptor agonists: Synthesis and pharmacological evaluation of trans,trans-configured perhydroquinoxalines.
AID138706Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID621888Displacement of [3H]Cl-DPDPE from human DOP receptor expressed in CHO cells after 60 mins by scintillation counting2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
AID1197353Displacement of [3H]DADLE from human recombinant opioid delta receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method2015European journal of medicinal chemistry, Mar-06, Volume: 92Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID365601Agonist activity at human kappa opioid receptor in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Structure-antitussive activity relationships of naltrindole derivatives. Identification of novel and potent antitussive agents.
AID147910Binding affinity for the Opioid receptor mu 11988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives.
AID149782Binding affinity of compound was determined against Opioid receptor delta 1 from a native receptor in guinea pig2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID749691Displacement of [3H]DADLE from human recombinant delta opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
AID148722Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for D105N point mutations; No binding1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID55440Binding constant against D216N,D217N,E218Q EL-2 Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID138846[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Mu opioid receptor in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID647796Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting2012European journal of medicinal chemistry, Apr, Volume: 50Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
AID724716Displacement of [3H]DPDPE from delta opioid receptor in mouse whole brain membranes without cerebellum after 1 hr by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
AID765827Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting2013European journal of medicinal chemistry, Sep, Volume: 67Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.
AID659121Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells assessed as calcium mobilization after 1 hrs by fluorescence analysis2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Semisynthetic neoclerodanes as kappa opioid receptor probes.
AID291860Antagonist activity at human delta opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID1875773Agonist activity at KOR in guinea pig brain membranes assessed as stimulation of [35S]GTPgammaS binding measured after 1 hr by liquid scintillation counting analysis relative to control2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved
AID148620Tested for inhibitory concentration against [3H]bremazocine binding to total sites of opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID149067Binding affinity against opioid receptor by displacing radioligand [3HlU69,5931994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
Antipodal alpha-N-(methyl through decyl)-N-normetazocines (5,9 alpha-dimethyl-2'-hydroxy-6,7-benzomorphans): in vitro and in vivo properties.
AID1820697Agonist activity at human kappa opioid receptor expressed in HEK293 assessed as increase in calcium mobilization incubated for 60 mins by FLIPR assay
AID149748Inhibitory concentration was determined against delta-opioid receptor using [3H]- DPDPE radioligand1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.
AID302203Efficacy at human kappa opioid receptor by [35S]GTPgammaS binding assay relative to U69,5932007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
AID152217Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes under unblocked condition2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID378996Agonist activity at human kappa opioid receptor expressed in CHO cells relative by [35S]GTPgammaS binding to U695932006Journal of natural products, Jan, Volume: 69, Issue:1
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
AID229800Ratio of Ki at mu-opioid receptor to Ki at kappa oioid receptor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives.
AID149844Binding affinity against Opioid receptor kappa 1 in guinea pig.1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
AID1441557Agonist activity at recombinant human kappa-type opioid receptor expressed in HEK293 cells at 1 uM after 30 mins by [35S]GTPgammaS binding assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.
AID302202Agonist activity at human kappa opioid receptor by [35S]GTPgammaS binding assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
AID291859Antagonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID621019Displacement of [3H]N/OFQ from human NOP receptor expressed in CHO cells after 60 mins by scintillation counting2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
AID148228Binding affinity determined against Opioid receptor delta 1 from human cloned receptor2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
AID233862Selectivity between mu opioid receptor and delta opioid receptor.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
AID141494Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID488650Selectivity ratio of Ki for mu opioid receptor to kappa opioid receptor2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.
AID268680Displacement of radiolabeled NalBzOH from kappa3 opioid receptor in Hartley guinea pig brain2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
AID1232261Binding affinity to rat kappa opioid receptor expressed in HEK293 cell membranes2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.
AID268069Stimulation of [35S]GTP-gamma-S binding at kappa opioid receptor in human brain cortical membrane2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
AID141263Binding affinity towards mutant E203Q,D204N,D206N,E209Q Opioid receptor kappa 1 EL-2 expressed in HEK cells2000Journal of medicinal chemistry, Apr-06, Volume: 43, Issue:7
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1129823Agonist activity at GFP-fused kappa opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.
AID151601Binding affinity at Opioid receptor mu 1 by displacement of [3H]DAMGO in rat brain membrane2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID1574663Displacement of [3H]U-69,593 from KOR in guinea pig brain membranes after 120 mins by scintillation counting method2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.
AID1224135Displacement of [3H]U-69593 from kappa-opioid receptor in guinea pig brain membrane2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Combination of cyclohexane and piperazine based κ-opioid receptor agonists: Synthesis and pharmacological evaluation of trans,trans-configured perhydroquinoxalines.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346411Rat kappa receptor (Opioid receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Nov-01, Volume: 90, Issue:21
Cloning and pharmacological characterization of a rat kappa opioid receptor.
AID1346411Rat kappa receptor (Opioid receptors)1993The Biochemical journal, Nov-01, Volume: 295 ( Pt 3)Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1985European journal of pharmacology, Feb-26, Volume: 109, Issue:2
[3H]U-69593 a highly selective ligand for the opioid kappa receptor.
AID1346341Mouse kappa receptor (Opioid receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jul-15, Volume: 90, Issue:14
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346329Human kappa receptor (Opioid receptors)1995Proceedings of the National Academy of Sciences of the United States of America, Jul-18, Volume: 92, Issue:15
kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (515)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (7.77)18.7374
1990's245 (47.57)18.2507
2000's142 (27.57)29.6817
2010's74 (14.37)24.3611
2020's14 (2.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.17 (24.57)
Research Supply Index6.26 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other522 (99.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]